NICE recommends dropping two drugs from Cancer Drugs Fund

Click for article

Click for article

Two drugs currently provided under the Cancer Drugs Fund (CDF) should cease to be available because they are not cost effective, the National Institute for Health and Care Excellence (NICE) has concluded.

Everolimus for breast cancer (Afinitor, Novartis) and ibrutinib for mantle cell lymphoma (Imbruvica, Janssen) do not meet the grade, says NICE in draft guidance now open for consultation.Nice_logo

Patients to get the latest drugs and treatments more quickly

courtesy of  Dept of Health – Media Centre

The NHS will have to comply with NICE guidance on new drugs and treatments or explain to patients why there is a delay, under a new scheme announced today.

This will help end the unfair practice where some parts of the NHS delay offering new treatment while other areas make them available straight away.

This regime, expected to be fully implemented by the Autumn, will be made up of three different parts:

  • Publishing an ‘innovation scorecard’ which will allow patients and the public to see which organisations are quickly adopting the latest NICE-approved drugs and treatments;
  • The NHS will have no excuse not to provide the latest NICE-approved drugs and treatments. They will be automatically added onto lists of what drugs are available in local areas, which will be published for all to see. This means new drugs and treatments will be automatically made available for doctors to prescribe across the NHS; and
  • Making uptake of new drugs and treatments quicker by helping the NHS overcome any barriers, by setting up a new group to help local NHS organisations implement NICE guidelines. New drugs and treatments can mean the NHS has to make big changes to the way they provide services, which can be a complicated process. The new group will help spread best practice and make uptake by the NHS quicker for patients.